CAHNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends June 30
CARDINAL HEALTH INC
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 10-K on Aug 11, 2026
$252.65−1.41 (-0.55%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 34.9
- Dividend yield
- 0.81%
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
3.8%−0.3 pts over 5 years
Operating margin
1.0%+0.7 pts over 5 years
Net margin
0.7%+0.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +14.2% | +7.4% | +9.4% | +7.7% | |
| Gross profit | +19.7% | +12.4% | +7.6% | +4.1% | |
| Operating income | +14.9% | +51.5% | +40.8% | +0.6% | |
| Net income | +9.8% | +73.2% | +22.9% | +1.8% | |
| EPS, diluted | +12.1% | +79.0% | +28.3% | +5.3% | |
| Free cash flow | +144.6% | +24.2% | +17.4% | +6.1% | |
| Dividend per share | +1.0% | +1.0% | +1.0% | +2.8% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | 19.3% | 34.1% | -60.5% | |
| Return on assets | 3.5% | 1.4% | 3.1% | |
| Current ratio | 1.34 | 1.12 | 0.88 | |
| Debt to equity | 1.65 | 3.48 | -3.08 | |
| Net debt to EBITDA | 1.54× | 2.27× | 1.13× | |
| Interest coverage | 10.5× | 2.6× | 7.5× | |
| Inventory turnover | 11.3× | 11.2× | 14.3× | |
| Capex to revenue | 0.3% | 0.2% | 0.3% | |
| Diluted shares | 320M | 294M | 237M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Cardinal Health generated $17.35B from operations and spent $11.02B on capital expenditure, dividends and share buybacks. 23% of that went back into the business.
Generated
$17.35B
Used
$11.02B
Capital expenditure$2.58B23%Dividends$2.57B23%Share buybacks$5.87B53%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin0.7%
×Asset turnover4.61×
×Equity multiplier-19.50×
=Return on equity, FY2026-60.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 0.7% | 4.61× | -19.50× | -60.5% |
| FY2025 | 0.7% | 4.53× | -16.39× | -52.1% |
| FY2024 | 0.4% | 5.13× | -14.34× | -27.6% |
| FY2023 | 0.2% | 4.70× | -23.79× | -18.0% |
| FY2022 | -0.5% | 4.11× | 81.64× | -173.4% |
| FY2021 | 0.4% | 3.81× | 23.80× | 34.1% |
| FY2020 | -2.4% | 3.74× | 10.07× | -91.1% |
| FY2019 | 0.9% | 3.60× | 6.53× | 22.0% |
| FY2018 | 0.2% | 3.42× | 6.22× | 4.0% |
| FY2017 | 1.0% | 3.50× | 5.56× | 19.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
6of 9 tests passed in fiscal 2026. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$1.71B
- Cash generatingOperating cash flow above zero$5.17B
- Return on assets improvedROA up on the prior year3.5% → 3.2%
- Earnings backed by cashOperating cash flow above net income$5.17B vs $1.71B
- Less leverageLong-term debt to assets fell15.0% → 12.2%
- Better liquidityCurrent ratio rose0.94 → 0.88
- No dilutionShare count did not rise242M → 237M
- Gross margin improvedGross margin up on the prior year3.67% → 3.84%
- More efficientAsset turnover rose4.93 → 4.79